Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has received an average recommendation of “Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.71.

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $15.00 price objective (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, February 26th. Finally, Benchmark reaffirmed a “buy” rating on shares of Humacyte in a report on Thursday, February 27th.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Woodline Partners LP grew its stake in Humacyte by 235.7% during the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares during the period. State Street Corp grew its stake in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares during the period. CenterBook Partners LP acquired a new stake in Humacyte during the fourth quarter worth approximately $6,463,000. Brevan Howard Capital Management LP grew its stake in Humacyte by 2,795.1% during the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock worth $4,426,000 after purchasing an additional 846,070 shares during the period. Finally, Vanguard Group Inc. grew its stake in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Performance

NASDAQ:HUMA opened at $3.06 on Tuesday. The stock has a fifty day moving average price of $4.33 and a 200-day moving average price of $4.92. The company has a market cap of $385.13 million, a price-to-earnings ratio of -2.28 and a beta of 1.30. Humacyte has a fifty-two week low of $2.81 and a fifty-two week high of $9.97.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.